Edwards Lifesciences Corporation
EW · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5,440 | $5,010 | $5,382 | $5,233 |
| % Growth | 8.6% | -6.9% | 2.9% | – |
| Cost of Goods Sold | $1,118 | $1,037 | $1,167 | $1,226 |
| Gross Profit | $4,322 | $3,973 | $4,215 | $4,007 |
| % Margin | 79.5% | 79.3% | 78.3% | 76.6% |
| R&D Expenses | $1,053 | $963 | $945 | $903 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,789 | $1,583 | $1,568 | $1,493 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $101 | $0 | $0 | $0 |
| Operating Expenses | $2,943 | $2,545 | $2,513 | $2,396 |
| Operating Income | $1,379 | $1,427 | $1,702 | $1,610 |
| % Margin | 25.3% | 28.5% | 31.6% | 30.8% |
| Other Income/Exp. Net | $169 | -$55 | $65 | $92 |
| Pre-Tax Income | $1,548 | $1,372 | $1,767 | $1,702 |
| Tax Expense | $152 | $152 | $246 | $199 |
| Net Income | $4,175 | $1,402 | $1,522 | $1,503 |
| % Margin | 76.7% | 28% | 28.3% | 28.7% |
| EPS | 6.98 | 2.31 | 2.46 | 2.41 |
| % Growth | 202.2% | -6.1% | 2.1% | – |
| EPS Diluted | 6.97 | 2.3 | 2.44 | 2.38 |
| Weighted Avg Shares Out | 598 | 607 | 619 | 623 |
| Weighted Avg Shares Out Dil | 599 | 609 | 624 | 631 |
| Supplemental Information | – | – | – | – |
| Interest Income | $120 | $67 | $36 | $17 |
| Interest Expense | $20 | $18 | $26 | $25 |
| Depreciation & Amortization | $155 | $145 | $167 | $163 |
| EBITDA | $1,723 | $1,535 | $1,960 | $1,890 |
| % Margin | 31.7% | 30.6% | 36.4% | 36.1% |